Table 1.
Baseline participant characteristics.
| Intervention group (N = 15) | Control group (N = 15) | |
|---|---|---|
| Age, years | 73.7 ± 10.5 | 71.7 ± 7.3 |
| Gender, female:male | 8:7 | 6:9 |
| BMI, kg/m2 | 28.9 ± 5.2 | 29.2 ± 5.3 |
| Ever smoker, n (%) | 9 (60) | 10 (67) |
| Duration of diagnosis, years | 3 (2, 8) | 3 (2, 6) |
| Diagnosis, n (%) | ||
| IPF | 5 (33) | 5 (33) |
| Non-IPF | 10 (67) | 10 (67) |
| Asbestosis | – | 1 |
| CTD-ILD | 6 | 3 |
| Drug-induced ILD | 1 | – |
| Fibrotic HP | 1 | 3 |
| Non-specific interstitial pneumonia | 1 | 1 |
| Unclassifiable ILD | 1 | 2 |
| FEV1/FVC | 77.6 ± 6.0 | 79.3 ± 8.0 |
| FEV1 (% pred) | 78.2 ± 18.2 | 71.3 ± 15.0 |
| FVC (% pred) | 77.6 ± 18.0 | 68.2 ± 15.3 |
| DLCO (% pred) | 42.1 ± 11.5 | 41.7 ± 12.2 |
| mMRC dyspnoea score | 2 (2, 3) | 2 (2, 3) |
| Domiciliary oxygen therapy, n (%) | 2 (13) | 5 (33) |
| ILD therapies, n (%) | ||
| Anti-fibrotic therapy | 4 (27) | 4(27) |
| Immunosuppressant therapy | 6 (40) | 7 (47) |
| Inhaler therapies, n (%) | ||
| Inhaled corticosteroid + long-acting beta-agonist | 3 (20) | 1 (7) |
| Long-acting muscarinic antagonist | 1 (7) | 1 (7) |
| Short-acting beta-agonist | 5 (33) | 2 (13) |
| Pulmonary rehabilitation in the previous 6 months, n (%) | 7 (47) | 8 (53) |
Data are expressed as mean ± standard deviation or median (interquartile range), except where indicated.
BMI body mass index, CTD-ILD connective tissues disease-related interstitial lung disease, DLCO diffusing capacity for carbon monoxide, FEV1 forced expiratory volume in one second, FVC forced vital capacity, HP hypersensitivity pneumonitis, ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, mMRC modified Medical Research Council.